13F Holdings
中文EN

ADPT Adaptive Biotechnologies Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1478320 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.9%
TTM net income YoY11.4%
TTM EPS YoY13.5%
Revenue 3-yr CAGR18.4%
Net income 3-yr CAGR—

Margins

Gross margin74.2%
Operating margin-16.2%
Net margin-23.7%
FCF margin-3.0%
EBITDA margin-11.6%

Returns

ROE-37.1%
ROA-12.0%
ROIC (approx.)-19.9%
Asset turnover0.51x

Leverage & solvency

Liabilities / assets73.1%
Debt / equity0.00x
Current ratio3.97x
Interest coverage-5.33x

Cash quality & payout

Operating cash flow / net income0.06x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$276.98M$178.96M$170.28M$185.31M$154.34M
Cost of revenue$71.36M$72.08M$75.55M$57.91M$49.30M
Gross profit$205.62M$106.88M$94.72M$127.40M$105.04M
R&D expense$93.77M$102.95M$122.12M$141.76M$142.34M
SG&A expense$72.70M$72.81M$83.93M$88.53M$74.50M
Operating income-$57.12M-$162.55M-$227.03M-$200.19M-$208.97M
Interest expense$11.78M$11.58M$13.80M$4.24M—
Pretax income-$59.46M-$159.59M-$225.30M-$200.37M-$207.30M
Income tax$0$0$0——
Net income-$59.50M-$159.49M-$225.25M-$200.19M-$207.28M
EBITDA-$41.12M-$145.11M-$207.44M-$179.27M-$196.71M
EPS (basic)-0.39-1.08-1.56-1.40-1.48
EPS (diluted)-0.39-1.08-1.56-1.40-1.48
Weighted avg. shares (diluted)151.72M147.10M144.38M142.52M140.35M
Balance sheet
Cash & equivalents$70.50M$47.92M$65.06M$90.03M$139.06M
Short-term investments$156.49M$174.37M$281.34M$408.17M$214.00M
Receivables$50.37M$41.73M$37.97M$40.06M$17.41M
Inventory$9.82M$8.44M$14.45M$14.45M$19.26M
Current assets$300.19M$283.75M$410.19M$562.15M$402.75M
PP&E, net$34.11M$48.62M$68.23M$83.45M$85.26M
Goodwill$118.97M$118.97M$118.97M$118.97M$118.97M
Intangibles$1.73M$3.42M$5.13M$6.83M$8.53M
Total assets$512.74M$539.38M$661.13M$856.62M$923.34M
Current liabilities$89.92M$98.05M$88.02M$109.79M$113.81M
Short-term debt$4.64M$865,000———
Long-term debt$126.57M$132.41M$130.66M$125.36M—
Total debt$131.21M$133.28M$130.66M$125.36M—
Total liabilities$287.74M$336.89M$352.86M$392.52M$319.24M
Shareholders' equity$218.79M$202.71M$308.40M$464.17M$603.99M
Net debt$60.71M$85.36M$65.60M$35.33M—
Shares outstanding153.78M147.77M145.08M143.11M141.39M
Cash flow statement
Operating cash flow-$45.99M-$95.21M-$156.32M-$183.94M-$192.73M
Capital expenditure$2.96M$3.66M$10.70M$16.35M$61.75M
Free cash flow-$48.95M-$98.88M-$167.02M-$200.29M-$254.47M
Investing cash flow$37.95M$77.79M$129.65M$2.90M$181.21M
Financing cash flow$30.40M$241,000$2.25M$132.26M$27.15M
Depreciation & amortization$16.00M$17.44M$19.60M$20.92M$12.25M
Stock-based compensation$51.48M$53.61M$62.91M$55.48M$43.25M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.